A kind of anti-lap monoclonal antibody, its antigen-binding fragment and application thereof

A monoclonal antibody and binding fragment technology, applied in the direction of antibodies, applications, antibody medical components, etc., can solve serious and limited clinical benefits and other problems, and achieve the effect of improving tumor immune response

Active Publication Date: 2022-05-10
BEIJING DONGFANG BIOTECH
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Small-molecule inhibitors of ALK5 targeting TGFβ type I receptor kinase or antibodies that simultaneously block the three isoforms of TGFβ1, TGFβ2, and TGFβ3 exhibited severe heart valve virulence in mice, rats, and dogs, implying that Broad-spectrum inhibition of signaling pathways driven by one or more isoforms limits the clinical benefit of this class of drugs
LAP is the protein cage of TGFβ1, which locks mature TGFβ1 in the latent complex. Drugs acting on the target of LAP can regulate the release or inhibition of TGFβ1 by regulating the structure of the LAP-TGFβ1 complex, thereby regulating the active pathway mediated by TGFβ1. At present, there is no drug of the same variety on the market at home and abroad. In order to meet the market demand, it is urgent to develop an anti-LAP monoclonal antibody that can regulate the release of TGFβ1 and improve the tumor microenvironment, its antigen-binding fragment and its application

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of anti-lap monoclonal antibody, its antigen-binding fragment and application thereof
  • A kind of anti-lap monoclonal antibody, its antigen-binding fragment and application thereof
  • A kind of anti-lap monoclonal antibody, its antigen-binding fragment and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0052] Example 1 of the present invention provides an anti-LAP monoclonal antibody or an antigen-binding fragment thereof, comprising a heavy chain variable region and a light chain variable region, and the amino acid sequence of HCDR1 in the heavy chain variable region is selected from SEQ ID NO : 1, SEQ ID NO: 7, SEQ ID NO: 13, SEQ ID NO: 19, SEQ ID NO: 24 or SEQ ID NO: 30; the amino acid sequence of the HCDR2 of the heavy chain variable region is selected from SEQ ID NO: 2. SEQ ID NO: 8, SEQ ID NO: 14, SEQ ID NO: 20, SEQ ID NO: 25 or SEQ ID NO: 31; the amino acid sequence of HCDR3 of the heavy chain variable region is selected from SEQ ID NO: 3 , SEQ ID NO: 9, SEQ ID NO: 15, SEQ ID NO: 21, SEQ ID NO: 26 or SEQ ID NO: 32; the amino acid sequence of the LCDR1 of the light chain variable region is selected from SEQ ID NO: 4, SEQ ID NO: 10, SEQ ID NO: 16, SEQ ID NO: 22, SEQ ID NO: 27 or SEQ ID NO: 33; the amino acid sequence of the LCDR2 of the light chain variable region is se...

Embodiment 2

[0054] In Example 2 of the present invention, an anti-LAP monoclonal antibody was obtained by immunizing mice with LAP antigen, optimizing the immunization method, and creating a phage display library. The anti-LAP monoclonal antibody or its antigen-binding fragment obtained by screening was selected from any of the following kind:

[0055]

Embodiment 3

[0057] Example 3 of the present invention specifically provides a screening method for anti-LAP single-chain antibody on the basis of Example 2 as follows: Step 1: LAP antigen immunization of mice

[0058] 1. Experimental animals:

[0059] Species and strains: BALB / c, female, mouse; body weight: 18-20g;

[0060] Laboratory animal provider: Beijing Huafukang Biotechnology Co., Ltd.

[0061] 2. Immunization: the mice were immunized, and the immune antigen was human LAP (a gene synthesized by Nanjing KingScript Biotechnology Co., Ltd., the company constructed a vector and expressed and purified it).

[0062] Step 2: Construction of phage antibody library

[0063]Take mouse splenocytes with higher titer, use Trizol reagent (purchased from Ambion, article number: 15596026), extract total RNA in mouse splenocytes, obtain cDNA by RT-PCR, use cDNA as a template, and use degenerate primers ( The degenerate primer reference used: Journal of Immunological Methods 233 (2000) 167-177) f...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
weightaaaaaaaaaa
Login to view more

Abstract

The present invention relates to the field of biomedicine, and provides an anti-LAP monoclonal antibody or an antigen-binding fragment thereof, including heavy chain variable regions HCDR1, HCDR2, HCDR3 and light chain variable regions LCDR1, LCDR2, LCDR3. The anti-LAP monoclonal antibody provided by the present invention inhibits the release of TGFβ1 from the source, deletes suppressive T cells, improves tumor immune response, can be used in combination with various immunotherapy drugs, and can be extended to more types of cancer and autoimmune diseases And fibrotic diseases, with huge clinical needs and huge market potential; cancers are selected from non-small cell lung cancer, colorectal cancer, pancreatic cancer, kidney cancer, gastric cancer, liver cancer, ovarian cancer, breast cancer, melanoma or glioma; Fibrotic diseases include pulmonary fibrosis or liver fibrosis; autoimmune diseases are selected from systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, dermatomyositis, polymyositis, vasculitis or Sjogren's disease.

Description

technical field [0001] The invention relates to the technical field of biomedicine, in particular to an anti-LAP monoclonal antibody, an antigen-binding fragment thereof and applications thereof. Background technique [0002] Cancer immunotherapy is to use the body's immune mechanism to enhance the patient's immune function through active or passive methods to achieve the purpose of killing tumor cells. Currently, cancer immune checkpoint inhibitor therapy has made breakthroughs and durable cancer immunotherapy response and is gradually becoming the first-line standard of care for an increasing number of cancers. But there are still a large number of cancer patients who do not respond to this treatment, suggesting that there are other mechanisms that prevent the immune system from targeting tumor cells for elimination. [0003] In the current retrospective analysis of clinical data of cancer patients, the activation of TGFβ signaling pathway was found to be a key factor in ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): C07K16/18C12N15/13C12N15/85C12N5/10A61K39/395A61P35/00A61P11/00A61P1/16A61P37/02
CPCC07K16/18C12N15/85A61K39/39558A61K39/39533A61K39/39566A61P35/00A61P11/00A61P1/16A61P37/02C07K2317/56C07K2317/565A61K2039/505A61K2300/00
Inventor 白义
Owner BEIJING DONGFANG BIOTECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap